Trial reportAntiviral therapy2015
Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.
Trial report in Antiviral therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00192569 (Australian Trial in Acute Hepatitis C), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Australian Trial in Acute Hepatitis C
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs.Haemophilia : the official journal of the World Federation of Hemophilia · 2016Trial
- Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C.Diagnostics (Basel, Switzerland) · 2022Article
- The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting.Virusdisease · 2021Article
- Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients.Disease markers · 2018Article
- Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment.Scientific reports · 2017Article
- Molecular epidemiology of hepatitis C infections in Ningxia, China: genotype, phylogeny and mutation analysis.Virology journal · 2016Article
- Review
- Evaluation of the dynamic pattern of viral evolution in patients with virological breakthrough during treatment with nucleoside/nucleotide analogs by ultra‑deep pyrosequencing.Molecular medicine reports · 2016Article
- Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.Virology journal · 2015Article
- Review
- HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b.Hepatology international · 2015Article
- Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.World journal of gastroenterology · 2015Review
- Influence of host resistance on viral adaptation: hepatitis C virus as a case study.Infection and drug resistance · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundDirect-acting antivirals (DAAs) are predicted to transform hepatitis C therapy, yet little is known about the prevalence of naturally occurring resistance mutations in recently acquired HCV. This study aimed to determine the prevalence and frequency of drug resistance mutations in the viral quasispecies among HIV-positive and -negative individuals with recent HCV.
methodsThe NS3 protease, NS5A and NS5B polymerase genes were amplified from 50 genotype 1a participants of the Australian Trial in Acute Hepatitis C. Amino acid variations at sites known to be associated with possible drug resistance were analysed by ultra-deep pyrosequencing.
resultsA total of 12% of individuals harboured dominant resistance mutations, while 36% demonstrated non-dominant resistant variants below that detectable by bulk sequencing (that is, <20%) but above a threshold of 1%. Resistance variants (<1%) were observed at most sites associated with DAA resistance from all classes, with the exception of sofosbuvir.
conclusionsDominant resistant mutations were uncommonly observed in the setting of recent HCV. However, low-level mutations to all DAA classes were observed by deep sequencing at the majority of sites and in most individuals. The significance of these variants and impact on future treatment options remains to be determined. Clinicaltrials.gov NCT00192569.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.